No Data
No Data
Raymond James Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Maintains Target Price $32
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year
ARS Pharmaceuticals: Strategic Growth and Market Penetration Justify Buy Rating
Raymond James Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Raises Target Price to $32
Scotiabank Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Maintains Target Price $30
ARS Pharmaceuticals' Earnings Call Highlights Growth and Challenges
mohd ammi bin ismail : hello